Five Prime Therapeutics reported $0 in Debt for its fourth fiscal quarter of 2020.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Debt Change
Amgen AMGN:US $ 32782M 97M
Astrazeneca AZN:US $ 27495M 7363M
AstraZeneca AZN:LN 27495M 7363M
Bristol Myers Squibb BMY:US $ 45158M 1124M
Clovis Oncology CLVS:US $ 64.35M 564.25M
Cytokinetics CYTK:US $ 137.39M 1.68M
Daiichi Sankyo 4568:JP Y 183739M 42434M
Eli Lilly And LLY:US $ 16515.1M 310.6M
GlaxoSmithKline GSK:LN 25483M 736M
Glaxosmithkline GSK:US $ 25483M 736M
Halozyme Therapeutics HALO:US $ 873.77M 476.54M
Immunogen IMGN:US $ 1.1M 1M
Ironwood Pharmaceuticals IRWD:US $ 436.08M 5.82M
Karyopharm Therapeutics KPTI:US $ 241.79M 50.78M
Macrogenics MGNX:US $ 0M 0M
Novartis NVS:US $ 35769M 2030M
Novartis NOVN:VX SF 35769M 2030M
Sangamo Biosciences SGMO:US $ 0M 0M
Xencor XNCR:US $ 0M 0M
Ziopharm Oncology ZIOP:US $ 0M 0M